Lipocine (LPCN) Property, Plant & Equipment (Net) Growth (3y) (2015 - 2025)
Lipocine (LPCN) Property, Plant & Equipment (Net) Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.05% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.65% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 411.50% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -3.34% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 16.78% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.66% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 109.44% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 19.96% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lipocine | 11.15 Mn | -12.76 Mn | - | -7.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.46% |
| Sep 30, 2025 | 47.15% |
| Jun 30, 2025 | 49.39% |
| Mar 31, 2025 | 66.67% |
| Dec 31, 2024 | 183.94% |
| Sep 30, 2023 | 363.13% |
| Jun 30, 2023 | 297.31% |
| Mar 31, 2023 | 262.07% |
| Dec 31, 2022 | 233.30% |
| Sep 30, 2022 | 71.55% |
| Jun 30, 2022 | 52.53% |
| Mar 31, 2022 | 28.73% |
| Dec 31, 2021 | -27.59% |
| Sep 30, 2020 | -75.85% |
| Jun 30, 2020 | -72.02% |
| Mar 31, 2020 | -69.42% |
| Dec 31, 2019 | -67.49% |
| Sep 30, 2019 | -59.51% |
| Jun 30, 2019 | -54.53% |
| Mar 31, 2019 | -48.10% |